Systems Genetics Reveals the Functional Context of PCOS Loci and Identifies Genetic and Molecular Mechanisms of Disease Heterogeneity

PLoS Genetics

Volumn 11, Issue 8, 2015, Pages

  Jones, Michelle R ^a   Brower, Meredith A ^b   Xu, Ning ^a   Cui, Jinrui ^a   Mengesha, Emebet ^a   Chen, Yii Der I ^c   Taylor, Kent D ^c   Azziz, Ricardo ^d   Goodarzi, Mark O ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HIGH MOBILITY GROUP A2 PROTEIN; INSULIN RECEPTOR; LUTEINIZING HORMONE RECEPTOR; RAB PROTEIN; SUMO 1 PROTEIN; TRANSCRIPTOME;

ADULT; ARTICLE; C9ORF3 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDD1A GENE; DNA METHYLATION; EPIGENETICS; FEMALE; FERRIMAN GALLWEY SCORE; GENE; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HMGA2 GENE; HORMONE RELEASE; HUMAN; HUMAN TISSUE; INSR GENE; INSULIN RESISTANCE; LHCGR GENE; OBESITY; OVARY POLYCYSTIC DISEASE; QUANTITATIVE TRAIT LOCUS; RAB5B GENE; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STON1 GTF2A1L GENE; SUBCUTANEOUS FAT; SUMO1P1 GENE; SUOX GENE; SYSTEMS BIOLOGY; TOX3 GENE; YAP1 GENE; CASE CONTROL STUDY; CPG ISLAND; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM;

ADULT; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; SUBCUTANEOUS FAT; SYSTEMS BIOLOGY; TRANSCRIPTOME;

EID: 84940762484     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1005455     Document Type: Article

References (52)

1. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R, Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–31. doi: 10.1038/nrendo.2010.217 21263450
2. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE, Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92(12):4546–56. 18056778
3. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI, Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100–4. 16219714
4. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43(1):55–9. Epub 2010/12/15. doi: 10.1038/ng.732 21151128
5. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012;44(9):1020–5. Epub 2012/08/14. doi: 10.1038/ng.2384 22885925
6. Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen YD, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet. 2012;49(2):90–5. Epub 2011/12/20. doi: 10.1136/jmedgenet-2011-100427 22180642
7. Welt CK, Styrkarsdottir U, Ehrmann DA, Thorleifsson G, Arason G, Gudmundsson JA, et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012;97(7):E1342–7. Epub 2012/05/02. doi: 10.1210/jc.2011-3478 22547425
8. Mutharasan P, Galdones E, Penalver Bernabe B, Garcia OA, Jafari N, Shea LD, et al. Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J Clin Endocrinol Metab. 2013;98(1):E185–90. Epub 2012/11/03. doi: 10.1210/jc.2012-2471 23118426
9. Louwers YV, Stolk L, Uitterlinden AG, Laven JS, Cross-Ethnic Meta-analysis of Genetic Variants for Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2013. Epub 2013/10/10.
10. Brower MA, Jones MR, Rotter JI, Krauss RM, Legro RS, Azziz R, et al. Further Investigation in Europeans of Susceptibility Variants for Polycystic Ovary Syndrome Discovered in Genome-wide Association Studies of Chinese Individuals. J Clin Endocrinol Metab. 2014:jc20142689.
11. Comim FV, Teerds K, Hardy K, Franks S, Increased protein expression of LHCG receptor and 17alpha-hydroxylase/17-20-lyase in human polycystic ovaries. Hum Reprod. 2013;28(11):3086–92. Epub 2013/09/10. doi: 10.1093/humrep/det352 24014605
12. Wang P, Zhao H, Li T, Zhang W, Wu K, Li M, et al. Hypomethylation of the LH/choriogonadotropin receptor promoter region is a potential mechanism underlying susceptibility to polycystic ovary syndrome. Endocrinology. 2014;155(4):1445–52. doi: 10.1210/en.2013-1764 24527662
13. McAllister JM, Modi B, Miller BA, Biegler J, Bruggeman R, Legro RS, et al. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci U S A. 2014;111(15):E1519–27. doi: 10.1073/pnas.1400574111 24706793
14. Grundberg E, Meduri E, Sandling JK, Hedman AK, Keildson S, Buil A, et al. Global analysis of DNA methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal regulatory elements. Am J Hum Genet. 2013;93(5):876–90. doi: 10.1016/j.ajhg.2013.10.004 24183450
15. Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, Hod E, et al. Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet. 2008;40(7):904–8. doi: 10.1038/ng.174 18568024
16. Ciaraldi TP, Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity. J Pediatr Endocrinol Metab. 2000;13 Suppl 5:1291–3. Epub 2000/12/16. 11117672
17. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR, Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009;94(1):157–63. doi: 10.1210/jc.2008-1492 18854391
18. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA, Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989;320(9):559–65. 2521688
19. Arroyo A, Laughlin GA, Morales AJ, Yen SS, Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab. 1997;82(11):3728–33. 9360532
20. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F, Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest. 1976;57(5):1320–9. 770505
21. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD, Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab. 1991;73(4):811–7. 1909705
22. Lobo RA, Kletzky OA, Campeau JD, diZerega GS, Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome. Fertil Steril. 1983;39(5):674–8. 6220924
23. Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86(12):5925–33. 11739466
24. Gilling-Smith C, Willis DS, Beard RW, Franks S, Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994;79(4):1158–65. 7962289
25. The Genotype-Expression Project 2015 [cited 2015 14 May 2015]. http://www.gtexportal.org.
26. Diamanti-Kandarakis E, Dunaif A, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030. doi: 10.1210/er.2011-1034 23065822
27. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777–84. doi: 10.1093/humrep/des463 23315061
28. Dunaif A, Segal KR, Futterweit W, Dobrjansky A, Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–74. 2670645
29. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72(1):83–9. 1898744
30. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F, Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83(6):2001–5. 9626131
31. Wu S, Divall S, Wondisford F, Wolfe A, Reproductive tissues maintain insulin sensitivity in diet-induced obesity. Diabetes. 2012;61(1):114–23. doi: 10.2337/db11-0956 22076926
32. Moran C, Arriaga M, Arechavaleta-Velasco F, Moran S, Adrenal androgen excess and body mass index in polycystic ovary syndrome. J Clin Endocrinol Metab. 2015:jc00009999. 25565293
33. Gehring NH, Lamprinaki S, Kulozik AE, Hentze MW, Disassembly of exon junction complexes by PYM. Cell. 2009;137(3):536–48. doi: 10.1016/j.cell.2009.02.042 19410547
34. Diem MD, Chan CC, Younis I, Dreyfuss G, PYM binds the cytoplasmic exon-junction complex and ribosomes to enhance translation of spliced mRNAs. Nat Struct Mol Biol. 2007;14(12):1173–9. 18026120
35. Hirota Y, Kuronita T, Fujita H, Tanaka Y, A role for Rab5 activity in the biogenesis of endosomal and lysosomal compartments. Biochem Biophys Res Commun. 2007;364(1):40–7. 17927960
36. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42(Database issue):D1001–6. Epub 2013/12/10. doi: 10.1093/nar/gkt1229 24316577
37. Allaire PD, Marat AL, Dall'Armi C, Di Paolo G, McPherson PS, Ritter B, The Connecdenn DENN domain: a GEF for Rab35 mediating cargo-specific exit from early endosomes. Mol Cell. 2010;37(3):370–82. doi: 10.1016/j.molcel.2009.12.037 20159556
38. Pan F, Yu H, Dang EV, Barbi J, Pan X, Grosso JF, et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science. 2009;325(5944):1142–6. doi: 10.1126/science.1176077 19696312
39. Duleba AJ, Dokras A, Is PCOS an inflammatory process? Fertil Steril. 2012;97(1):7–12. doi: 10.1016/j.fertnstert.2011.11.023 22192135
40. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, Khera A, et al. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol. 2007;27(9):2043–9. 17626902
41. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL, Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab. 2004;89(2):806–11. 14764799
42. Orio F, Jr.Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(1):2–5. 15483098
43. Chang W, Goodarzi MO, Williams H, Magoffin DA, Pall M, Azziz R, Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. Fertil Steril. 2008;90(6):2291–7. doi: 10.1016/j.fertnstert.2007.10.025 18178198
44. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88. Epub 2008/10/28. doi: 10.1016/j.fertnstert.2008.06.035 18950759
45. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO, The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–9. 15181052
46. Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS, A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet. 2005;37(5):549–54. 15838508
47. Gunderson KL, Steemers FJ, Ren H, Ng P, Zhou L, Tsan C, et al. Whole-genome genotyping. Methods Enzymol. 2006;410:359–76. 16938560
48. Davis S DP, Bilke S, Triche T, Jr., Bootwalla M. Methylumi: Handle Illumina Methylation Data. R package version 2.12.02014.
49. Smyth G, Gentleman R CV, Dudoit S, Irizarry R, Huber W, Limma: Linear Models for Microarray Data. New York: Springer; 2005.
50. Benjamini Y, Hochberg Y, Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological). 1995:289–300.
51. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41(Database issue):D991–5. doi: 10.1093/nar/gks1193 23193258
52. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res. 2013;41(Database issue):D56–63. doi: 10.1093/nar/gks1172 23193274